Program
domvanalimab
Also written as “Domvanalimab” and “Domvanalimab (DOM)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Adenocarcinoma Of Esophagus · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.
Drug pageDomvanalimab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 55 open or running | phase 3since Aug 12, 2022 | Apr 26, 2018 | Mar 2027phase 2 · NCT06727565 |
| Arcus Biosciencesits history only | 40 open or running | phase 3since Oct 3, 2022 | Jul 26, 2018 | none ahead |
| AstraZeneca | 11 open or running | phase 3since Jan 11, 2022 | Jan 11, 2022 | none ahead |
Also a collaborator on its studies: Otsuka and Merck KGaA, Darmstadt, Germany.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named domvanalimabINNProposed as its International Nonproprietary Name in WHO's List 124
- Jan 11, 2022First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05211895 · 791 enrolled · United States, Belgium, Brazil and more
TargetBeta
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), ”NCIt, by rule
“T-cell immunoreceptor with Ig and ITIM domains inhibitor”ChEMBL 37, by rule
Other programs on TIGIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| BC008-1Arule | sichuan-luzhou-buchang-biopharmaceutical-co-ltd | phase 1 | 2 |
Studies
The one study AstraZeneca leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05211895Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Aug 10, 2026 | 791 |
How it is read
Names in the registry
- “Domvanalimab”, 9 entries
- “Domvanalimab (DOM)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Adenocarcinoma Of Esophagus, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.